NCT04317105: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

NCT04317105
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PI3K, PTEN
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: All breast cancer patients are eligible for the dose escalation portion of the clinical trial; Patients must have at least one actionable molecular aberration in the PIK3CA or PTEN gene to be eligible for dose expansion cohorts
Exclusions: Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis that require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT04317105

Comments are closed.

Up ↑